Alpha fetoprotein (AFP) response and efficacy outcomes in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)

Authors
Category Primary study
JournalOncology Research and Treatment
Year 2020
This article has no abstract
Epistemonikos ID: 955353d1f76a05c0d87cea2087a558e3e0af8a74
First added on: Nov 22, 2025